ROYALTY PHARMA PLC- CL A (RPRX) Stock Fundamental Analysis

NASDAQ:RPRX • GB00BMVP7Y09

45.23 USD
+0.43 (+0.96%)
Last: Feb 13, 2026, 09:31 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Overall RPRX gets a fundamental rating of 5 out of 10. We evaluated RPRX against 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of RPRX get a neutral evaluation. Nothing too spectacular is happening here. RPRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year RPRX was profitable.
  • RPRX had a positive operating cash flow in the past year.
  • Of the past 5 years RPRX 4 years were profitable.
  • RPRX had a positive operating cash flow in 4 of the past 5 years.
RPRX Yearly Net Income VS EBIT VS OCF VS FCFRPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

  • The Return On Assets of RPRX (3.95%) is better than 84.82% of its industry peers.
  • RPRX has a Return On Equity of 11.93%. This is amongst the best in the industry. RPRX outperforms 85.86% of its industry peers.
  • The Return On Invested Capital of RPRX (6.43%) is better than 84.29% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for RPRX is significantly below the industry average of 12.66%.
  • The 3 year average ROIC (5.98%) for RPRX is below the current ROIC(6.43%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.95%
ROE 11.93%
ROIC 6.43%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
RPRX Yearly ROA, ROE, ROICRPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • RPRX has a better Profit Margin (32.55%) than 95.29% of its industry peers.
  • In the last couple of years the Profit Margin of RPRX has declined.
  • With an excellent Operating Margin value of 65.22%, RPRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • RPRX's Operating Margin has declined in the last couple of years.
Industry RankSector Rank
OM 65.22%
PM (TTM) 32.55%
GM N/A
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
RPRX Yearly Profit, Operating, Gross MarginsRPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • RPRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for RPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RPRX Yearly Shares OutstandingRPRX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
RPRX Yearly Total Debt VS Total AssetsRPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

  • An Altman-Z score of 1.83 indicates that RPRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • RPRX has a Altman-Z score of 1.83. This is comparable to the rest of the industry: RPRX outperforms 59.16% of its industry peers.
  • RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
  • RPRX has a Debt to FCF ratio of 9.47. This is in the better half of the industry: RPRX outperforms 79.58% of its industry peers.
  • RPRX has a Debt/Equity ratio of 1.34. This is a high value indicating a heavy dependency on external financing.
  • RPRX's Debt to Equity ratio of 1.34 is on the low side compared to the rest of the industry. RPRX is outperformed by 75.92% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 9.47
Altman-Z 1.83
ROIC/WACC0.74
WACC8.69%
RPRX Yearly LT Debt VS Equity VS FCFRPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

  • A Current Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
  • The Current ratio of RPRX (3.48) is comparable to the rest of the industry.
  • RPRX has a Quick Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.48, RPRX perfoms like the industry average, outperforming 57.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.48
Quick Ratio 3.48
RPRX Yearly Current Assets VS Current LiabilitesRPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • RPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.80%.
  • RPRX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.39% yearly.
EPS 1Y (TTM)7.8%
EPS 3Y6.39%
EPS 5YN/A
EPS Q2Q%26.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.14%

3.2 Future

  • RPRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.87% yearly.
  • The Revenue is expected to grow by 8.88% on average over the next years. This is quite good.
EPS Next Y17.35%
EPS Next 2Y15.67%
EPS Next 3Y16.21%
EPS Next 5Y10.87%
Revenue Next Year2.09%
Revenue Next 2Y4.56%
Revenue Next 3Y9.3%
Revenue Next 5Y8.88%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
RPRX Yearly Revenue VS EstimatesRPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
RPRX Yearly EPS VS EstimatesRPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 10.23, the valuation of RPRX can be described as reasonable.
  • Based on the Price/Earnings ratio, RPRX is valued cheaper than 90.58% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.67. RPRX is valued rather cheaply when compared to this.
  • With a Price/Forward Earnings ratio of 8.72, the valuation of RPRX can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, RPRX is valued cheaper than 91.10% of the companies in the same industry.
  • RPRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.69.
Industry RankSector Rank
PE 10.23
Fwd PE 8.72
RPRX Price Earnings VS Forward Price EarningsRPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • RPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RPRX is cheaper than 82.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF 27.64
EV/EBITDA N/A
RPRX Per share dataRPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of RPRX may justify a higher PE ratio.
  • RPRX's earnings are expected to grow with 16.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.59
PEG (5Y)N/A
EPS Next 2Y15.67%
EPS Next 3Y16.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 2.10%, RPRX has a reasonable but not impressive dividend return.
  • RPRX's Dividend Yield is rather good when compared to the industry average which is at 0.93. RPRX pays more dividend than 92.67% of the companies in the same industry.
  • RPRX's Dividend Yield is comparable with the S&P500 average which is at 1.80.
Industry RankSector Rank
Dividend Yield 2.1%

5.2 History

  • RPRX has been paying a dividend for over 5 years, so it has already some track record.
  • RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
RPRX Yearly Dividends per shareRPRX Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • RPRX pays out 49.36% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y15.67%
EPS Next 3Y16.21%
RPRX Yearly Income VS Free CF VS DividendRPRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B
RPRX Dividend Payout.RPRX Dividend Payout, showing the Payout Ratio.RPRX Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (2/13/2026, 9:31:07 AM)

45.23

+0.43 (+0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)05-06
Inst Owners81.5%
Inst Owner Change-1.3%
Ins Owners1.56%
Ins Owner Change-1.45%
Market Cap26.11B
Revenue(TTM)N/A
Net Income(TTM)764.96M
Analysts85.71
Price Target48.57 (7.38%)
Short Float %7.09%
Short Ratio6.84
Dividend
Industry RankSector Rank
Dividend Yield 2.1%
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date02-20
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)4.81%
PT rev (3m)9.5%
EPS NQ rev (1m)2.76%
EPS NQ rev (3m)1.5%
EPS NY rev (1m)-3.01%
EPS NY rev (3m)1.8%
Revenue NQ rev (1m)0.95%
Revenue NQ rev (3m)2.79%
Revenue NY rev (1m)1.44%
Revenue NY rev (3m)2.56%
Valuation
Industry RankSector Rank
PE 10.23
Fwd PE 8.72
P/S 11.11
P/FCF 27.64
P/OCF 10.86
P/B 4.07
P/tB 4.76
EV/EBITDA N/A
EPS(TTM)4.42
EY9.77%
EPS(NY)5.19
Fwd EY11.47%
FCF(TTM)1.64
FCFY3.62%
OCF(TTM)4.17
OCFY9.21%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.59
PEG (5Y)N/A
Graham Number33.24
Profitability
Industry RankSector Rank
ROA 3.95%
ROE 11.93%
ROCE 8.15%
ROIC 6.43%
ROICexc 7.12%
ROICexgc 7.53%
OM 65.22%
PM (TTM) 32.55%
GM N/A
FCFM 40.2%
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 1.34
Debt/FCF 9.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 62.15%
Interest Coverage -5.67
Cash Conversion N/A
Profit Quality 123.5%
Current Ratio 3.48
Quick Ratio 3.48
Altman-Z 1.83
F-Score5
WACC8.69%
ROIC/WACC0.74
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.8%
EPS 3Y6.39%
EPS 5YN/A
EPS Q2Q%26.96%
EPS Next Y17.35%
EPS Next 2Y15.67%
EPS Next 3Y16.21%
EPS Next 5Y10.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%47.14%
Revenue Next Year2.09%
Revenue Next 2Y4.56%
Revenue Next 3Y9.3%
Revenue Next 5Y8.88%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year30.98%
EBIT Next 3Y14.48%
EBIT Next 5Y13.68%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%

ROYALTY PHARMA PLC- CL A / RPRX FAQ

Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?

ChartMill assigns a fundamental rating of 5 / 10 to RPRX.


What is the valuation status for RPRX stock?

ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.


How profitable is ROYALTY PHARMA PLC- CL A (RPRX) stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for RPRX stock?

The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 10.23 and the Price/Book (PB) ratio is 4.07.


Can you provide the dividend sustainability for RPRX stock?

The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.